Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRIS NASDAQ:SABS NASDAQ:SGMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRISCuris$0.49-4.5%$0.66$0.49▼$3.13$19.11M3.08347,567 shs244,861 shsSABSSAB Biotherapeutics$3.70-4.9%$3.86$1.60▼$6.60$188.52M0.551.04 million shs942,440 shsSGMOSangamo Therapeutics$0.14-0.4%$0.27$0.10▼$0.77$55.93M1.049.11 million shs4.17 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRISCuris0.00%-12.62%-17.07%-57.37%-75.49%SABSSAB Biotherapeutics0.00%-9.98%-5.61%-3.90%+100.00%SGMOSangamo Therapeutics0.00%+17.39%-50.00%-65.11%-69.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRISCuris$0.49-4.5%$0.66$0.49▼$3.13$19.11M3.08347,567 shs244,861 shsSABSSAB Biotherapeutics$3.70-4.9%$3.86$1.60▼$6.60$188.52M0.551.04 million shs942,440 shsSGMOSangamo Therapeutics$0.14-0.4%$0.27$0.10▼$0.77$55.93M1.049.11 million shs4.17 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRISCuris0.00%-12.62%-17.07%-57.37%-75.49%SABSSAB Biotherapeutics0.00%-9.98%-5.61%-3.90%+100.00%SGMOSangamo Therapeutics0.00%+17.39%-50.00%-65.11%-69.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRISCuris 2.00Hold$17.003,367.97% UpsideSABSSAB Biotherapeutics 2.75Moderate Buy$11.00197.30% UpsideSGMOSangamo Therapeutics 1.75Reduce$5.503,974.07% UpsideCurrent Analyst Ratings BreakdownLatest CRIS, SABS, and SGMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026SABSSAB Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $10.005/11/2026SABSSAB Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/11/2026SABSSAB Biotherapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.004/20/2026CRISCuris Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026SGMOSangamo Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/10/2026SABSSAB Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)4/2/2026SABSSAB Biotherapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.003/20/2026CRISCuris HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.003/12/2026SABSSAB Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/11/2026SABSSAB Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $14.003/10/2026SABSSAB Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $7.00(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRISCuris$9.44M2.02N/AN/A$0.33 per share1.49SABSSAB Biotherapeutics$1.32M142.81$0.34 per share10.83$4.46 per share0.83SGMOSangamo Therapeutics$39.55M1.41N/AN/A($0.04) per share-3.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRISCuris-$7.58M-$1.19N/AN/AN/A-80.29%N/A-181.57%8/4/2026 (Estimated)SABSSAB Biotherapeutics$13.27M-$2.11N/AN/AN/AN/A-0.29%-0.25%N/ASGMOSangamo Therapeutics-$122.93M-$0.44N/AN/AN/A-310.81%-2,662.06%-132.12%N/ALatest CRIS, SABS, and SGMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026CRISCuris-$0.3267-$1.25-$0.9233-$1.25$1.69 millionN/A5/12/2026Q1 2026SABSSAB Biotherapeutics-$0.20-$0.35-$0.15-$0.35$0.13 millionN/A3/19/2026Q4 2025CRISCuris-$0.4325-$0.50-$0.0675$1.23$3.25 million$1.14 million3/9/2026Q4 2025SABSSAB Biotherapeutics-$0.16-$0.46-$0.30-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRISCurisN/AN/AN/AN/AN/ASABSSAB BiotherapeuticsN/AN/AN/AN/AN/ASGMOSangamo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRISCurisN/A1.110.49SABSSAB Biotherapeutics0.0111.459.46SGMOSangamo TherapeuticsN/A0.840.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRISCuris29.97%SABSSAB Biotherapeutics7.82%SGMOSangamo Therapeutics56.92%Insider OwnershipCompanyInsider OwnershipCRISCuris5.42%SABSSAB Biotherapeutics25.06%SGMOSangamo Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRISCuris6038.98 million36.87 millionNo DataSABSSAB Biotherapeutics14050.95 million38.18 millionNot OptionableSGMOSangamo Therapeutics480414.28 million397.29 millionOptionableCRIS, SABS, and SGMO HeadlinesRecent News About These CompaniesSangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call TranscriptMay 16 at 8:31 AM | insidermonkey.comSangamo Therapeutics Inc (SGMO) Q1 2026 Earnings Call Highlights: Progress Amidst Financial ...May 16 at 8:16 AM | finance.yahoo.comSangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the PeriodMay 16 at 2:10 AM | tipranks.comSangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call TranscriptMay 14 at 7:02 PM | seekingalpha.comSangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue EstimatesMay 14 at 6:17 PM | zacks.comSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial ResultsMay 14 at 4:01 PM | globenewswire.comSangamo Therapeutics Announces First Quarter 2026 Earnings CallMay 11, 2026 | markets.businessinsider.comSangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture MarketMay 5, 2026 | finanznachrichten.deSangamo Therapeutics (SGMO) to Release Earnings on MondayMay 4, 2026 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest UpdateMay 1, 2026 | marketbeat.comSangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)April 30, 2026 | globenewswire.comSangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB marketApril 29, 2026 | finance.yahoo.comSangamo Therapeutics Announces Transition to Trading on OTCQB Venture MarketApril 29, 2026 | globenewswire.comSangamo Therapeutics (NASDAQ:SGMO) Insider Sells $17,456.75 in StockApril 24, 2026 | insidertrades.comGregory Davis Sells 69,827 Shares of Sangamo Therapeutics (NASDAQ:SGMO) StockApril 23, 2026 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) SVP Sells $89,944.92 in StockApril 23, 2026 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Lowered to Strong Sell Rating by Zacks ResearchApril 18, 2026 | marketbeat.comSangamo Therapeutics Faces Rising Trade Policy Risks, Higher Costs and Global Growth UncertaintyApril 1, 2026 | tipranks.comSangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial ResultsMarch 31, 2026 | finanznachrichten.deWhy PEPG, SGMO, PHR are among top premarket losers todayMarch 31, 2026 | msn.comSangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and ...March 31, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Shopify’s Valuation Crisis Creates Opportunity in 2026By Thomas Hughes | May 5, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026CRIS, SABS, and SGMO Company DescriptionsCuris NASDAQ:CRIS$0.49 -0.02 (-4.50%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.50 +0.01 (+1.18%) As of 05/15/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.SAB Biotherapeutics NASDAQ:SABS$3.70 -0.19 (-4.88%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$3.76 +0.06 (+1.76%) As of 05/15/2026 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.Sangamo Therapeutics NASDAQ:SGMO$0.14 0.00 (-0.37%) As of 05/15/2026 03:59 PM EasternSangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
